BioNTech price target raised to $203 from $191 at Canaccord

Canaccord analyst William Maughan raised the firm’s price target on BioNTech to $203 from $191 and keeps a Buy rating on the shares. The analyst said we think that its shares remain undervalued on the COVID opportunity alone. And with a steadily advancing oncology pipeline poised to potentially add value and several infectious disease opportunities with data in 2023, there is room for additional upside.